Optimal dilution of the recombinant CD91 antibody should be determined by the researcher.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.2 mg/mL
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Aliquot the recombinant CD91 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Target
LRP1
(Low Density Lipoprotein Receptor-Related Protein 1 (LRP1))
Andere Bezeichnung
CD91
Hintergrund
Members of the LDL receptor gene family, including LDLR (low density lipoprotein receptor), LEP1 (low density lipoprotein related protein), megalin (also designated GP330), VLDLR (very low density lipoprotein receptor) and apoER2 are characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar domain. LRP1, also designated LRP and Alpha-2-Macroglobulin receptor, is an endocytic receptor that mediates the uptake of at least 15 ligands, including Alpha-2-Macroglobulin and apoE. LRP1 is cleaved into a membrane subunit and an extracellular subunit, which remain non-covalently associated. Proper folding and trafficking of LRP1 is facilitated by the receptor-associated protein (RAP), a molecular chaperone. The uptake of all known ligands through LRP1 can be blocked by RAP, which induces a conformational change in the receptor that renders it unable to bind ligands. LRP1, which is expressed in brain, liver and lung, is also implicated in Alzheimer s disease (AD), as the human LRP gene localizes to a potential AD locus on chromosome 12.